US$ 25.92
glp 1 drug market GLP-1 Receptor Agonist Size & Analysis, 2026-2033 GLP-1 Receptor Agonist Market Size
Description
Li, Z., Chen, X., Vong, J

The company says it is planning to initiate a Phase III development program with amycretin for adults with overweight or obesity during the first quarter of 2026

Mopelola Adeyemo

2020;5(6):e131429

Implications for Plastic Surgery The growing use of GLP-1 RAs for the management of T2DM and weight loss is giving rise to a new patient population with distinct clinical needs
10.1517/13543784.17.10.1559 151 RichterB.Bandeira-EchtlerE.BergerhoffK.LerchC
